Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The state of immune activation may guide targeted immunotherapy in sepsis. In a double-blind, double-dummy randomized clinical study, 240 patients with sepsis due to lung infection, bacteremia, or acute cholangitis were subjected to measurements of serum ferritin and HLA-DR/CD14. Patients with macrophage activation-like syndrome (MALS) or immunoparalysis were randomized to treatment with anakinra or recombinant interferon-gamma or placebo. Twenty-eight-day mortality was the primary endpoint; sepsis immune classification was the secondary endpoint. Using ferritin >4,420 ng/mL and <5,000 HLA-DR receptors/monocytes as biomarkers, patients were classified into MALS (20.0%), immunoparalysis (42.9%), and intermediate (37.1%). Mortality was 79.1%, 66.9%, and 41.6%, respectively. Survival after 7 days with SOFA score decrease was achieved in 42.9% of patients of the immunotherapy arm and 10.0% of the placebo arm (p = 0.042). Three independent immune classification strata are recognized in sepsis. MALS and immunoparalysis are proposed as stratification for personalized adjuvant immunotherapy. Clinicaltrials.gov registration NCT03332225.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · Nature Reviews Immunology · doi:10.1038/nri3552 · Cited by 2,772
Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
Döcke, W.-D., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., Volk, H.-D., & Kox, W. (1997) · Nature Medicine · doi:10.1038/nm0697-678 · Cited by 1,190
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
Cited by
The pathophysiology of sepsis and precision-medicine-based immunotherapy
Giamarellos-Bourboulis, E. J., Aschenbrenner, A. C., Bauer, M., Bock, C., Calandra, T., Gat-Viks, I., Kyriazopoulou, E., Lupse, M., Monneret, G., Pickkers, P., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01660-5 · Cited by 374
Self-citationImmune dysregulation in sepsis: experiences, lessons and perspectives
Cao, M., Wang, G., & Xie, J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01766-7 · Cited by 259
Multi-Omics Endotypes in ICU Sepsis-Induced Immunosuppression
Garduno, A., Cusack, R., Leone, M., Einav, S., & Martin-Loeches, I. (2023) · Microorganisms · doi:10.3390/microorganisms11051119 · Cited by 39
“More precisely, patients with MALS were noted to have a lower absolute count of platelets and prolonged activated partial thromboplastin time (aPTT), and higher levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin [131].”
BackgroundLing, H., Lin, Y., Bao, W., Xu, N., Chen, L., Zhao, L., Liu, C., Shen, Y., Zhang, D., Gong, Y., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115072 · Cited by 14
He, T. T., Jiao, T. Q., & An, X. M. (2026) · PeerJ · doi:10.7717/peerj.20770 · Cited by 2
Metadata
- Authors
- Leventogiannis, K., Kyriazopoulou, E., Antonakos, N., Kotsaki, A., Tsangaris, I., Markopoulou, D., Grondman, I., Rovina, N., Theodorou, V., Antoniadou, E., Koutsodimitropoulos, I., Dalekos, G., Vlachogianni, G., Akinosoglou, K., Koulouras, V., Komnos, A., Kontopoulou, T., Prekates, A., Koutsoukou, A., van der Meer, J. W. M., Dimopoulos, G., Kyprianou, M., Netea, M. G., & Giamarellos-Bourboulis, E. J.
- Venue
- Cell Reports Medicine
- Publisher
- Elsevier BV
- Published
- 2022-11
- Volume
- 3
- Issue
- 11
- Pages
- 100817
- ISSN
- 2666-3791 (ISSN-L)
- OpenAlex
- W4309333178
- Cited by
- 150
- References
- 5
- FWCI
- 14.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial. https://app.cochat.ai/papers/10.1016/j.xcrm.2022.100817
- The paper
- Leventogiannis, K., Kyriazopoulou, E., Antonakos, N., Kotsaki, A., Tsangaris, I., Markopoulou, D., Grondman, I., Rovina, N., Theodorou, V., Antoniadou, E., Koutsodimitropoulos, I., Dalekos, G., Vlachogianni, G., Akinosoglou, K., Koulouras, V., Komnos, A., Kontopoulou, T., Prekates, A., Koutsoukou, A., . . . Giamarellos-Bourboulis, E. J. (2022). Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2022.100817
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.